On January 12, 2026 Amplia therapeutics reported interim data from Phase 2a ACCENT trial in metastatic pancreatic cancer has been presented at the 2026 American Society for Clinical Oncology: Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation, delivered by Amplia’s Chief Medical Officer Dr Jason Lickliter, highlights updated efficacy and safety data for narmafotinib in combination with standard chemotherapy (gemcitabine and AbraxaneÒ).
Key points from the poster include:
The updated progression-free survival (PFS) is 7.7 months, compared to 5.5 months for Gemcitabine and Abraxane alone
The overall response rate (ORR) is 35%; this increases to 42% when including unconfirmed responses
Narmafotinib continues to be well tolerated by patients with the adverse effect profile of the narmafotinib-chemotherapy combination similar to chemotherapy alone
Amplia CEO, Dr Chris Burns, commented:
"We are pleased to present our research findings to clinicians and scientists at this conference, one of the world’s premier pancreatic cancer meetings. Presenting at ASCO (Free ASCO Whitepaper) GI positions Amplia among leading biotechnology and pharmaceutical companies internationally and underscores the company’s exciting progress in the development of narmafotinib in pancreatic cancer."
(Press release, Amplia Therapeutics, JAN 12, 2026, View Source [SID1234661923])